A phase II study of gemcitabine and cisplatin combination as induction chemotherapy for untreated locally advanced cervical carcinoma

Dueñas‐González, Alfonso; López-Graniel, C.; González, A.; Reyes, M.; Mota, A.; Muñoz, Daniel; Solorza, Gilberto; Hinojosa, Luz María; Guadarrama, R.; Florentino, Rodrigo M.; Mohar, Alejandro; Melendez, Jose; Maldonado, Vilma; Chanona, J.; Robles, Enrique Rosales; Garza, Jaime de la

doi:10.1023/a:1011117617514

Cited by 57 publications

(20 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 5 shows the results of the present study in comparison to those of previous reports (Sugiyama et al, 1999;Hwang et al, 2001;Dueñas-Gonzalez et al, 2001;D'Agostino et al, 2002;Di Vagno et al, 2003;Dueñas-Gonzalez et al, 2003;Umesaki et al, 2004; and this study. Table 5.…”

Section: Discussionsupporting

confidence: 64%

Neoadjuvant Chemotherapy Using Platinum-Based Regimens for Stage Ib2-II Squamous Cell Carcinoma and Non-Squamous Cell Carcinoma of the Cervix

Shoji¹,

Takatori²,

Omi³

et al. 2012

Squamous Cell Carcinoma

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 64%

Neoadjuvant Chemotherapy Using Platinum-Based Regimens for Stage Ib2-II Squamous Cell Carcinoma and Non-Squamous Cell Carcinoma of the Cervix

Shoji¹,

Takatori²,

Omi³

et al. 2012

Squamous Cell Carcinoma

View full text Add to dashboard Cite

“…[15][16][17] A previous study combining gemcitabine with cisplatin as first-line chemotherapy for this patient population has shown very encouraging tumor activity, with an overall response rate of 95%. 12 In an attempt to increase the response rate, and based on in vitro studies showing that gemcitabine oxaliplatin produces a higher synergy than gemcitabine cisplatin, we decided to test this novel combination in patients with untreated cervical carcinoma. We decided to use a 21-day schedule with gemcitabine days 1and 8 at 1,250 mg/m 2 and oxaliplatin at 130 mg/m 2 based on a phase I trial reported by Mavroudis et al 14 in which gemcitabine to 1,600 mg/m 2 days 1 and 8, and oxaliplatin 120 mg/m 2 was the dose recommended for phase II studies.…”

Section: Discussionmentioning

confidence: 99%

“…10 In addition, clinical studies have demonstrated that the combination of gemcitabine cisplatin is highly active in several tumor types, including recurrent 11 and untreated cervical carcinoma. 12 Experimental data on colon carcinoma and leukemia cell lines has shown that gemcitabine synergizes to a greater extent the cytotoxic action of oxaliplatin as compared with cisplatin. 13 In a phase I clinical study of the combination of oxaliplatin/gemcitabine in patients with advanced solid tumors, 14 among 30 evaluable patients a partial response was observed in 13%.…”

mentioning

confidence: 99%

Induction Chemotherapy With Gemcitabine and Oxaliplatin for Locally Advanced Cervical Carcinoma

Dueñas‐González

López-Graniel²,

González³

et al. 2003

American Journal of Clinical Oncology

View full text Add to dashboard Cite

Induction chemotherapy followed by surgery, particularly with newer agents or combinations, remains to be explored in locally advanced cervical cancer. Gemcitabine cisplatin is a very active combination for this tumor, therefore we explored the activity of gemcitabine in combination with oxaliplatin. Ten untreated patients with histologic diagnosis of cervical carcinoma and staged as IB2 to IIIB were treated with 3 21-day courses of oxaliplatin 130 mg/m day 1 and gemcitabine 1,250 mg/m days 1 and 8 followed by locoregional treatment with either surgery or concomitant chemoradiation. Response and toxicity were evaluated at the end of chemotherapy. All patients were evaluable. The overall clinical response rate was 80%, being complete in 3 patients (30%) and partial in 5 (50%). Seven (70%) patients underwent surgery, and three (30%) had chemoradiation as definitive treatment. Hematologic toxicity was moderate, with leukopenia grades III-IV in 17 and 0%; granulocytopenia grades III-IV in 23 and 3%, respectively. Eight patients had grade I oropharyngeal toxicity. At a median follow-up of 11 months (range: 10-12), all patients are disease free. Gemcitabine oxaliplatin is a very active and well-tolerated combination for locally advanced cervical cancer.

show abstract

“…Cisplatin has been the standard cytotoxic agent for treating advanced cervical cancer (20) and has been combined with other chemotherapeutic agents, including 5-fluorouracil (21), bleomycin (22), ifosfamide (23), gemcitabine (24), vinorelbine (25), paclitaxel (26)(27)(28) and topotecan (29).…”

Section: Discussionmentioning

confidence: 99%

Tetraarsenic oxide and cisplatin induce apoptotic synergism in cervical cancer

et al. 2013

View full text Add to dashboard Cite

Abstract. Tetraarsenic oxide (As 4 O 6 , TAO) is a new arsenic compound that inhibits cell growth and induces apoptosis in human cervical cancer cell lines. In the present study, we report that the growth of tumor cells (CaSki) was inhibited by treatment with TAO alone or in combination with cisplatin or paclitaxel in vitro and in vivo. Proliferation was assessed by WST-1 assay, and apoptosis was assessed by Annexin-V/ PI FACS analysis in the CaSki cell line treated with a single agent or with the combinations of two agents. Expression of apoptosis-related proteins was analyzed by western blot analysis. A mouse xenograft model using CaSki cells was used to determine the in vivo activity of tetraarsenic oxide alone and in combination with cisplatin or paclitaxel by estimation of tumor size. At the end of the experiment, tumor tissue from each mouse was removed and processed for TUNEL analysis for confirmation of apoptotic cells. TAO was able to inhibit cell proliferation in a time-and dose-dependent manner. A combination of TAO and cisplatin effectively induced apoptosis by activating caspase-3. Using a mouse xenograft model, the sizes of tumors which were treated with a single agent and with a combination of agents decreased in a time-dependent manner. A combination of TAO and cisplatin resulted in a significantly reduced tumor size (P<0.05). The data for the histochemical staining of TUNEL-positive cells showed that the number of apoptotic cells was significantly increased by the combination of TAO and cisplatin. Thus, TAO is a good candidate for use in a combined regimen with cisplatin for patients with cervical

show abstract

A phase II study of gemcitabine and cisplatin combination as induction chemotherapy for untreated locally advanced cervical carcinoma

Abstract: Induction chemotherapy with the combination of gemcitabine and cisplatin is highly active for untreated cervical cancer patients and has an acceptable toxicity profile.

Cited by 57 publications

References 29 publications

Neoadjuvant Chemotherapy Using Platinum-Based Regimens for Stage Ib2-II Squamous Cell Carcinoma and Non-Squamous Cell Carcinoma of the Cervix

Neoadjuvant Chemotherapy Using Platinum-Based Regimens for Stage Ib2-II Squamous Cell Carcinoma and Non-Squamous Cell Carcinoma of the Cervix

Induction Chemotherapy With Gemcitabine and Oxaliplatin for Locally Advanced Cervical Carcinoma

Tetraarsenic oxide and cisplatin induce apoptotic synergism in cervical cancer

Contact Info

Product

Resources

About